Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories

European Urology, Год журнала: 2017, Номер 72(4), С. 492 - 495

Опубликована: Март 22, 2017

Язык: Английский

---

BRCA2 and Other DDR Genes in Prostate Cancer

Cancers, Год журнала: 2019, Номер 11(3), С. 352 - 352

Опубликована: Март 12, 2019

Germline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent prostate cancer than previously recognized, with BRCA2 as the most commonly altered gene. mutations have been linked to poor prognosis when patients managed under protocols currently approved for cancer. The impact of germline other DDR beyond remain unclear. Importantly, a quarter identified mutation carriers lack family history clinical implications defects yet be elucidated. Poly ADP-ribose polymerase (PARP) inhibitors platinum-based chemotherapy proven effective treatment tumor types BRCA1 alterations several trials evaluating their efficacy Here, we summarize available evidence regarding prevalence cancer; association outcomes; assessing new therapies that exploit briefly discuss some uncertainties about appropriate management these patients.

Язык: Английский

---

Active surveillance for intermediate-risk prostate cancer

Prostate Cancer and Prostatic Diseases, Год журнала: 2016, Номер 20(1), С. 1 - 6

Опубликована: Ноя. 1, 2016

Язык: Английский

---

Understanding and targeting prostate cancer cell heterogeneity and plasticity

Seminars in Cancer Biology, Год журнала: 2021, Номер 82, С. 68 - 93

Опубликована: Ноя. 26, 2021

Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. tumors different patients manifest significant inter-patient heterogeneity with respect to histo-morphological presentations and molecular architecture. An individual patient tumor also harbors genetically distinct clones which PCa cells display intra-tumor features phenotypic marker expression. This inherent cell heterogeneity, e.g., the expression of androgen receptor (AR), constitutes barrier long-term therapeutic efficacy AR-targeting therapies. Furthermore, progression as well treatments induce plasticity such AR-positive may turn into AR-negative prostate switch lineage identity from adenocarcinomas neuroendocrine-like tumors. induced similarly confers resistance other In this review, I first discuss perspective an abnormal organ development deregulated cellular differentiation, luminal progenitor likely origin for PCa. then focus on intrinsic treatment-naïve presence stem (PCSCs). further elaborate by genetic alterations interventions, present potential strategies therapeutically tackle plasticity. My discussions will make it clear that, achieve enduring clinical efficacy, both need be targeted novel combinatorial approaches.

Язык: Английский

---

African-specific molecular taxonomy of prostate cancer

Nature, Год журнала: 2022, Номер 609(7927), С. 552 - 559

Опубликована: Авг. 31, 2022

Prostate cancer is characterized by considerable geo-ethnic disparity. African ancestry a significant risk factor, with mortality rates across sub-Saharan Africa of 2.7-fold higher than global averages

Язык: Английский

---